Indian injectables specialist Gland Pharma is aiming to establish a secondary manufacturing site for some of Chinese manufacturer Shanghai Henlius Biotech’s “key” biosimilar products, after signing an initial collaboration agreement with the firm that could begin to bear fruit in the coming years.
“We have signed a term sheet as a second site for their pipeline of products. So that would take probably two years from now, once the agreement is firmed up....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?